- Home
- SGMT vs GALT Comparison
SGMT vs GALT Comparison
Compare SGMT & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGMT | GALT |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.7M | 261.1M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGMT | GALT |
|---|---|---|
| Price | $5.90 | $4.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $29.71 | $8.50 |
| AVG Volume (30 Days) | 622.5K | ★ 794.2K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.73 | $0.84 |
| 52 Week High | $11.41 | $7.13 |
Technical Indicators
Market Signals| Indicator | SGMT | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 37.38 | 35.32 |
| Support Level | $5.92 | $3.90 |
| Resistance Level | $6.33 | $4.19 |
| Average True Range (ATR) | 0.35 | 0.62 |
| MACD | 0.02 | -0.24 |
| Stochastic Oscillator | 11.16 | 15.83 |
Price Performance
Historical ComparisonAbout SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.